ASCO: Novartis' Kisqali posts first-in-class survival win in younger women

Even before it launched, Novartis’ Kisqali was living in the shadow of classmate Ibrance, and it has been ever since. But with its latest data set, Kisqali now has an advantage the Pfizer blockbuster can’t boast.

In a phase 3 trial of premenopausal women with HR-positive, HER-2 negative breast cancer and no prior endocrine therapy, the combination of Kisqali, the hormone suppressant gosrelin, and either tamoxifen or an aromatase inhibitor cut the risk of death by 29% compared with endocrine therapy alone.